Syndax Pharmaceuticals announced that its Phase 2 trial for axatilimab in treating idiopathic pulmonary fibrosis failed to meet its primary endpoint, causing its stock to drop 2.59%. Following this, Pomerantz LLP launched an investigation into whether Syndax and some executives engaged in securities fraud or unlawful practices. Investors affected by the stock decline are encouraged to contact the law firm for potential class action participation. This investigation could lead to legal actions depending on findings about corporate conduct.
Syndax Pharmaceuticals' recent legal investigation news comes with this market context from Pluang's health sector data. For readers following health stocks, here is Pluang's market snapshot as of Oct 29, 2026 20:51 WIB: Out of 150 priced health-sector US stocks, 126 rose and 24 fell today. Notable movers include MESO (Mesoblast Limited) at USD 15.34 with a 14.56% increase and a typical hold time of 17 days, HLN (Haleon plc) at USD 8.66 down 13.35% with a 15-day hold, and LLY (Eli Lilly And Co) at USD 1,387.98 up 7.70%, with Pluang order activity showing 29% sell and 71% buy, and a typical hold time of 94 days.
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...
Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...
Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...
